2024-09-19-世界卫生组织-WHO_Global_Market_Study_on_RSV_Immunization_Products,_September_2024_11页_324kb

WHO Global Market Study on RSV Immunization Products

Summary

The World Health Organization (WHO) conducted a working document analysis on RSV immunization products, focusing on global demand, supply, pricing, and access challenges. The key findings are as follows:

1. RSV Disease and Current Interventions

Respiratory Syncytial Virus (RSV) is a leading cause of infant mortality and hospitalization in low- and middle-income countries (LMICs). While four maternal vaccines and three adult RSV vaccines, along with monoclonal antibodies (mAbs), are under development, only a few products are currently available. The burden of RSV is highest in infants and adults with comorbidities.

2. Market Overview

Based on data as of August 2024:

• Number of Authorized Products: 3 vaccines for older adults and pregnant women; 1 long-acting mAb for infants.
• Demand Forecast: By 2030, high-income countries (HICs) are expected to account for 70–80% of RSV product demand, with LMICs adopting products later due to affordability and infrastructure challenges.
• Supply: Current supply is projected to meet demand but depends on manufacturing scale-up and pricing strategies.

3. Pricing and Access Challenges

• Prices: RSV vaccines range from $75–$260 per dose in HICs, while infant mAbs cost $231–$730 per dose. mAbs are significantly more expensive than vaccines.
• Access Barriers: LICs and MICs face affordability issues due to tiered pricing and lack of financial resources. Supply constraints are expected for infant mAbs due to limited manufacturers and high production costs.

4. Key Actions for Equitable Access

• Market Shaping: Encourage tiered pricing, technology transfer, and Gavi support to reduce costs in low-resource settings.
• Demand Predictability: Generate evidence on cost-effectiveness and conduct transparent pricing analyses to inform country decisions.
• Collaboration: Strengthen partnerships between suppliers, global health organizations, and governments to ensure sustainable supply chains and infrastructure support.

This study highlights the urgency of addressing market dynamics to ensure equitable access to RSV immunization products.